The FDA doesn’t slap a black box warning on the label for no reason…side effects can be severe. Providers would monitor LFT’s as a result. That said I believe the allosteric inhibition is superior and by some strange luck Leronlimab has slipped the noose of side effects while providing more efficacious CCR5 receptor blockade. With approval they are writing the script for Leronlimab not Maraviroc.